Literature DB >> 12028788

The evolution of drug-resistant malaria: the role of drug elimination half-life.

Ian M Hastings1, William M Watkins, Nicholas J White.   

Abstract

This paper seeks to define and quantify the influence of drug elimination half-life on the evolution of antimalarial drug resistance. There are assumed to be three general classes of susceptibility of the malaria parasite Plasmodium falciparum to a drug: Res0, the original, susceptible wildtype; Res1, a group of intermediate levels of susceptibility that are more tolerant of the drug but still cleared by treatment; and Res2, which is completely resistant to the drug. Res1 and Res2 resistance both evolve much faster if the antimalarial drug has a long half-life. We show that previous models have significantly underestimated the rate of evolution of Res2 resistance by omitting the effects of drug half-life. The methodology has been extended to investigate (i) the effects of using drugs in combination, particularly when the components have differing half-lives, and (ii) the specific example of the development of resistance to the antimalarial pyrimethamine-sulphadoxine. An important detail of the model is the development of drug resistance in two separate phases. In phase A, Res1 is spreading and replacing the original sensitive forms while Res2 remains at a low level. Phase B starts once parasites are selected that can escape drug action (Res1 genotypes with borderline chemosensitivity, and Res2): these parasites are rapidly selected, a process that leads to widespread clinical failure. Drug treatment is clinically successful during phase A, and health workers may be unaware of the substantial changes in parasite population genetic structure that predicate the onset of phase B. Surveillance programs are essential, following the introduction of a new drug, to monitor effectively changes in treatment efficacy and thus provide advance warning of drug failure. The model is also applicable to the evolution of antibiotic resistance in bacteria: in particular, the need for these models to incorporate drug pharmacokinetics to avoid potentially large errors in their predictions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028788      PMCID: PMC1692966          DOI: 10.1098/rstb.2001.1036

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  35 in total

1.  Preventing antimalarial drug resistance through combinations.

Authors:  N J White
Journal:  Drug Resist Updat       Date:  1998-03       Impact factor: 18.500

Review 2.  The prevention of antimalarial drug resistance.

Authors:  W Peters
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

Authors:  S A Ward; W M Watkins; E Mberu; J E Saunders; D K Koech; H M Gilles; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

4.  A simple model of the build-up of resistance to mixtures of anti-malarial drugs.

Authors:  C F Curtis; L N Otoo
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

Review 5.  Modelling a predictable disaster: the rise and spread of drug-resistantmalaria.

Authors:  I M Hastings; U D'Alessandro
Journal:  Parasitol Today       Date:  2000-08

6.  Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. Part 4. Effects on incidence of malaria infection.

Authors:  F H Msuya; C F Curtis
Journal:  Acta Trop       Date:  1991-08       Impact factor: 3.112

7.  Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of Plasmodium falciparum infections in individuals exposed to variable levels of disease transmission.

Authors:  D Arnot
Journal:  Trans R Soc Trop Med Hyg       Date:  1998 Nov-Dec       Impact factor: 2.184

8.  Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.

Authors:  A M Nzila; E K Mberu; J Sulo; H Dayo; P A Winstanley; C H Sibley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay.

Authors:  P Teja-Isavadharm; F Nosten; D E Kyle; C Luxemburger; F Ter Kuile; J O Peggins; T G Brewer; N J White
Journal:  Br J Clin Pharmacol       Date:  1996-11       Impact factor: 4.335

10.  Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria.

Authors:  R N Price; F Nosten; C Luxemburger; A Kham; A Brockman; T Chongsuphajaisiddhi; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Sep-Oct       Impact factor: 2.184

View more
  60 in total

Review 1.  Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.

Authors:  Jürg Utzinger; Jennifer Keiser; Xiao Shuhua; Marcel Tanner; Burton H Singer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  History, dynamics, and public health importance of malaria parasite resistance.

Authors:  Ambrose O Talisuna; Peter Bloland; Umberto D'Alessandro
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

Review 3.  Resisting resistance: dealing with the irrepressible problem of malaria.

Authors:  Geoffrey Edwards; Giancarlo A Biagini
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

4.  Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.

Authors:  K Stepniewska; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

5.  Benefits of using multiple first-line therapies against malaria.

Authors:  Maciej F Boni; David L Smith; Ramanan Laxminarayan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

6.  The de novo selection of drug-resistant malaria parasites.

Authors:  N J White; W Pongtavornpinyo
Journal:  Proc Biol Sci       Date:  2003-03-07       Impact factor: 5.349

Review 7.  Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems.

Authors:  Ambrose O Talisuna; Corine Karema; Bernhards Ogutu; Elizabeth Juma; John Logedi; Andrew Nyandigisi; Modest Mulenga; Wilfred F Mbacham; Cally Roper; Philippe J Guerin; Umberto D'Alessandro; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2012-11       Impact factor: 25.071

Review 8.  Antimalarial drug resistance.

Authors:  Nicholas J White
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.

Authors:  Wirichada Pongtavornpinyo; Ian M Hastings; Arjen Dondorp; Lisa J White; Richard J Maude; Sompob Saralamba; Nicholas P Day; Nicholas J White; Maciej F Boni
Journal:  Evol Appl       Date:  2009-02       Impact factor: 5.183

10.  Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.

Authors:  Allen L Malisa; Richard J Pearce; Salim Abdulla; Hassan Mshinda; Patrick S Kachur; Peter Bloland; Cally Roper
Journal:  Malar J       Date:  2010-07-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.